Bradley Alexander McGregor

机构：Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center · ORCID：0000-0002-8298-0289

发表论文 519 篇 · 总被引 7926 次 · h-index 38

代表论文

• Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801) (2026 · Journal of Clinical Oncology · 被引 1)
• Lutetium-177-PSMA-617 ( 177 Lu-PSMA-617) in neuroendocrine prostate cancer (NEPC). (2026 · Journal of Clinical Oncology · 被引 1)
• A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801). (2026 · Journal of Clinical Oncology · 被引 1)
• 4 Baseline and Early On-Treatment Plasma Kidney Injury Molecule-1 (KIM-1) Levels are Associated with Outcomes in Advanced Renal Cell Carcinoma (aRCC) (2026 · The Oncologist)
• 49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma (2026 · The Oncologist)
• Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity (2026 · Clinical Cancer Research)